Drug Research
Thermo Fisher Scientific Introduces New Chromosomal Microarray with Two-Day Turnaround Time to Increase Lab Productivity
Thermo Fisher Scientific, the world leader in serving science, announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time. Providing insights on chromosomal variants for...
Drug Research
Unlocking Value-Based Pricing Strategies In Pharma CDMOs
Contract Development and Manufacturing Organizations (CDMOs), which pharmaceutical companies increasingly delegate product development and manufacturing, operate in a fragmented market undergoing substantial consolidation. Yet, many CDMOs fail to fully capitalize on pricing projects, risking competitiveness. To thrive, they must...
Drug Research
Small Molecule Innovator CDMO Market Poised For Huge Growth
The projected worth of the Global Small Molecule Innovator CDMO Market is anticipated to surpass $76.50 billion by 2031, displaying a compounded annual growth rate (CAGR) of 6.1% during the estimated timeframe. Contract Development and Manufacturing Organizations (CDMOs) offer...
Drug Research
Parexel, Partex Partner to Accelerate Drug Discovery and Development
Parexel, a CRO providing a full range of Phase I to IV clinical development services, and Partex, a digital pharma platform, entered a strategic alliance designed to leverage artificial intelligence (AI)-powered solutions to accelerate drug discovery and development for...
Drug Research
AGC Biologics, Asahi Kasei Enter Clinical Drug Substance Agreement
AGC Biologics, a global biopharmaceutical CDMO, entered a new agreement with Asahi Kasei Pharma to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.AGC Biologics will leverage its monoclonal antibody development and manufacturing experience to...
Drug Research
Chiesi, Aliada Therapeutics Enter Drug Delivery Alliance
Chiesi Global Rare Diseases has entered a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier (BBB)-crossing platform technology to address challenging disease areas with high unmet need.The collaboration will focus on multiple enzyme cargoes...
Drug Research
Croda Pharma introduces new bioprocessing solutions to replace banned materials
Croda Pharma has introduced a critical range of new bioprocessing detergents optimised for viral inactivation and cell lysis. The company’s new product range, Virodex™, offers an answer to the key market need for replacing the popular, but now banned,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read